| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -211.1% | n/a |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | 6.1 | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 19.1 | n/a |
| Pr/Book | 16.6 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 39.9% | n/a |
| PBT | n/a | n/a |
| EPS | -80.3% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 30-Jun-21 | 1.60 | (2.91) | (3.92)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-22 | 4.04 | (2.64) | (3.24)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-23 | 1.75 | (8.30) | (11.35)p | n/a | n/a | n/a | n/a | 0.0% |
| 30-Jun-24 | 0.86 | (3.14) | 0.71p | 0.9 | n/a | n/a | n/a | 0.0% |
| 30-Jun-25 | 1.20 | (2.57) | 0.14p | 2.9 | n/a | -80% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Full Year Results for the 12mths to 30 June 2025 | 14-Oct-2025 | 07:00 | RNS |
| New contract with top 10 pharma | 13-Oct-2025 | 07:00 | RNS |
| Notice of Results, Analyst & Investor Presentation | 10-Oct-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 0.85p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 1.30 |
| 52 Week Low | 0.22 |
| Volume | 3,346,005 |
| Shares Issued | 2,696.98m |
| Market Cap | £22.92m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:27 | 115,673 @ 0.87p |
| 16:19 | 18,632 @ 0.84p |
| 16:16 | 20,000 @ 0.84p |
| 14:32 | 1,147,787 @ 0.87p |
| 15:16 | 95,000 @ 0.84p |
| CEO | Arron Tolley |
| CFO | Andrew Rapson |
You are here: research